Therapy of follicular lymphoma - latest developments
Authors:
J. Mayer 1; A. Obořilová 1; I. Vášová 1; Z. Král 1; M. Matuška 2; D. Feltl 2
Authors‘ workplace:
Interní hematoonkologická klinika FN Brno
1; Radioterapeutická klinika FN s poliklinikou Ostrava
2
Published in:
Transfuze Hematol. dnes,13, 2007, No. 1, p. 4-11.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Follicular lymphoma (FL) belongs to the most common forms of non-Hodgkin’s lymphomas. This overview summarizes the important news regarding the therapy of FL from the past 5 years. In principle, in the therapy we can use: watch and wait strategy, radiotherapy, chemotherapy, rituximab, interferon alfa, ibritumomab, tositumomab, autologous hematopoietic stem cell transplantation, allogeneic transplantation, vaccines, and some other new drugs. The order of these therapeutic procedures does not mean this is the sequence in which they should be used. Since FL is a chronic, relapsing disease, a proper procedure(s) should be used in proper patients in a proper sequence. The clinical course of the disease as well as the therapy of FL are variable. Today, we also have to consider the cost of treatment. Therefore, it is necessary, FL patients are treated in experienced centers.
Key words:
follicular lymphoma, rituximab, interferon alfa, ibritumomab, allogeneic transplantation, autologous hematopoietic stem cell transplantation
Sources
1. Mayer J. Folikulární lymfomy. Lékařská fakulta Masarykovy univerzity Brno, Edice kontinuálního vzdělávání v medicíně, Brno, 2001; 86.
2. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 101: 1258–1265.
3. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 519–522.
4. Petersen PM, Gospodarowicz M, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiotherapy alone. Proceedings of ASCO 2004; abstract No 6521.
5. Seymour JF, Pro B, Fuller FM, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003; 21(11): 2115–2122.
6. Haas RLM, Poortmens P, de Jong BMP, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003; 21: 2474-2480.
7. Orina JN, Moore SG, Lechowicz MJ, Flowers CR. Determining the benefits of chemotherapy for achieving complete response in patients with untreated advanced stage follicular lymphoma: a systematic review and meta-analysis. Blood 2005; 106(11): abctract No 290.
8. Rigacci L, Federico M, Martelli M, et al. The role of anthracyclines in combination chemotherapy for treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfoni on 761 cases. Leukemia and Lymphoma 2003; 44: 1911–1917.
9. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005; 105: 4573–4575.
10. Nickening C, Dreyling M, Hoster E, et al. MCP (mitoxantrone/chlorambucil/prednisolone) chemotherapy impairs the subsequent collection of stem cells in comparing to CHOP induction in patients with indolent lymphomas – results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Blood 2005; 106(11): abstract No 3331.
11. Herold M, Schulze A, Niederwieser D, et al. BOP versus COP in advanced indolent lymphomas, results of a randomized multicenter phase III study of the East German Study Group Hematology/Oncology (OSHO). Blood 2002; 100(11): abstract No 3082.
12. Friedberg JW, Cohen P, Cheson BD, et al. Bendamustine HCL (Treanda) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-cell non-Hodgkin’s lymphoma: results from a phase II multicenter single-agent study (SDX-105-01). Blood 2005; 106(11): abstract No 229.
13. Rohatiner AZS, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223.
14. Mayer J. Klinické využití chimerické monoklonální protilátky Rituximab. Lékařská fakulta Masarykovy univerzity Brno, Edice kontinuálního vzdělávání v medicíně, Brno 2004; 71.
15. Chumchalová J, Trbušek M, Bukovská S, et al. Unexpected antagonistic effect of rituximab with procarbazine disclosed during an in vitro testing of rituximab–mediated sensitization of B-cell lines to commonly used anticancer drugs. Haematologica 2006; 91(Suppl. 1): abstract No 1119.
16. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCN alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071.
17. Van Oers MHJ, Van Glabbeke M, Teodorovic I, et al. Chimeric anti-CD20 monoclonal antibody (rituximab, Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: final analysis of a phase III randomized intergoup clinical trial. Blood 2005; 106:(11): abstract No 353.
18. Marcus R. Use of 90Y-Ibritumomab tiutexan in non-Hodgkin’s lymphoma. Semin Oncol 2005; 32(Suppl. 1): S36–S42.
19. Witzig TE, Gordon LI. Cabanillas F, et al. Randomized controlled trial of Yttrium -90-labelled ibritumomab tiutexan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20: 2453–2463.
20. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423.
21. Bierman PJ, Sweetenham JW, Loberiza FR, et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation - the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744–3753.
22. Van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529.
23. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: Results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.
24. Sebban C, Belanger C, Brousse N, et al. Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 trial. Blood 2003; 102(11): abstract No 354.
25. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667–2674.
26. Deconinc E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105: 3817–3823.
27. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732.
28. Doubek M, Ráčil Z, Mayer J. Klinické využití humanizované monoklonální protilátky ameltuzumab. Lékařská fakulta Masarykovy univerzity Brno, Edice kontinuálního vzdělávání v medicíně, Brno 2006; 103.
29. Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988; 25(2, Suppl. 2): 11–16.
30. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe D’Etude des Lymphomes Folliculaires. J Clin Oncol 1997; 15: 1110–1117.
31. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454–1459.
32. Herold M, Pasold R, Srock S, et al. Rituximab plus mitoxantrone, chlorambucil, prednisolon (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma – results of a phase III study (OSHO 39). Ann Oncol 2005; 16(Suppl. 5): abstract No 060.
33. Ladetto M, Ricca I, Benedetti F, et al. Rituximab-supplemented high-dose sequential chemotherapy has superior response rate and event-free survival compared to R-CHOP in poor risk follicular lymphoma at diagnosis: Results from a multicenter randomized GITMO trial. Blood 2005; 106(11): abstract No 675.
34. Foussard C, Mounier N, Van Hoof A, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma patients. J Clin Oncol 2006; 24(Suppl.): abstract No 7508.
35. Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: results of the E1496 phase III trial from Eastern Cooperative Oncology Group in the Cancer and Leukemia Group B. Blood 2005; 106(11): abstract No 349.
36. Hainsworth JD, Litchy S, Schaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–1095.
37. Ghielmini M, Schmitz SFH, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standards weekly x 4 schedule. Blood 2004; 103: 4416–4423.
38. Dreyling M, Forstpointner R, Gramatzki M, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. J Clin Oncol 2006; 24(Suppl.): abstract No 7502.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2007 Issue 1
Most read in this issue
- Results and complications of splenectomy in patients with severe thrombocytopenia in ITP resistant to initial conservative therapy – centre experience
- A relationship of serum imunoglobulin free light chain levels measurement to multiple myeloma staging
- From the monitoring of Bcr/Abl fusion gene level in patient with chronic myeloid leukemia to the imatinib resistance detection – case report
- Therapy of follicular lymphoma - latest developments